Melanoma. A multidisciplinary approach for the general surgeon

Area of Science:

• Oncology
• Surgical Oncology
• Immunology

Background:

• Melanoma treatment is increasingly multidisciplinary, requiring surgeons to stay abreast of biological and therapeutic advancements.
• Sentinel lymph node biopsy (SLNB) is crucial for accurate melanoma staging in patients with tumors >1 mm.
• Current adjuvant therapies, like interferon-alpha 2b (IFN-alpha 2b), have limitations regarding cost, toxicity, and efficacy in certain patient groups.

Purpose of the Study:

• To review the current understanding of melanoma biology and treatment advancements.
• To evaluate the role of SLNB and adjuvant therapies in melanoma management.
• To discuss the potential of novel immunotherapeutic strategies and molecular diagnostic tools.

Main Methods:

• Review of clinical trial data (ECOG-1684, ECOG-1690) and FDA approvals.
• Analysis of SLNB techniques, including serial sectioning and immunohistochemistry.
• Discussion of emerging adjuvant immunotherapies (GMK, PMCV, Melacine) and RT-PCR detection methods.

Main Results:

• SLNB is recommended for staging melanomas >1 mm to guide adjuvant therapy decisions.
• IFN-alpha 2b is approved for adjuvant treatment of thick primary tumors or resected nodal disease, but its use in node-negative disease is not supported.
• The efficacy of high-dose IFN-alpha 2b for resected nodal disease is uncertain, necessitating a risk-benefit assessment for individual patients.

Conclusions:

• SLNB analysis requires meticulous techniques to detect micrometastatic disease.
• Newer, less toxic immunotherapies are promising alternatives to IFN-alpha 2b for high-risk melanoma.
• RT-PCR detection of tyrosinase in SLNs can identify patients at high risk for recurrence, with ongoing trials to determine optimal management.